Business context and reporting period
Organovo Holdings, Inc. (with subsidiary Organovo, Inc.) filed this unaudited Form 10-Q for the three months ended June 30, 2013, its first fiscal quarter after changing its year-end to March 31. The filing describes a development-stage company developing 3D human tissues for drug research, biological research and potential therapeutic use; it had not generated significant revenue from its planned principal operations. The request metadata names Vivosim Labs, Inc., but the filing itself is for Organovo Holdings, Inc.—verify the intended issuer.
Financial results and liquidity
- Revenue: $106,000, down from $259,000 in the comparable 2012 quarter. Revenue comprised $94,000 from collaborations and $12,000 from grants; there was no product revenue.
- Expenses and losses: Selling, general and administrative expense was $2.378 million and research and development expense was $1.462 million. Operating loss was $3.734 million; net loss was $3.771 million, or $0.06 per basic and diluted share. Revenue was too limited for a meaningful positive margin assessment.
- Cash flow: Operating activities used $2.663 million; investing activities used $113,000; financing activities used $3,000. Cash and cash equivalents declined $2.779 million during the quarter.
- Balance sheet at June 30: Cash was $12.849 million; current assets were $13.261 million and current liabilities $7.580 million, yielding working capital of about $5.681 million and a current ratio of about 1.75. Total assets were $14.508 million and total liabilities $7.600 million.
- Debt and other obligations: Capital lease obligations totaled approximately $22,000. The company also reported $6.025 million of warrant liabilities, a derivative liability rather than conventional borrowing. Operating lease payments totaled $1.531 million.
- Accumulated deficit and equity: Accumulated deficit was $70.136 million; stockholders’ equity was $6.908 million. Shares outstanding at June 30 were 64.951 million.
Material changes versus the prior comparable period
- Revenue fell about 59%, primarily reflecting the planned phasing of collaboration deliverables, despite management’s statement that overall collaborative research activity was increasing.
- Operating expenses rose about 124%, from approximately $1.7 million to $3.8 million. Management cited expanded staffing, higher stock-based compensation, increased laboratory spending and facility costs. Full-time employees increased from 21 to 35, including research and development staff rising from 14 to 24.
- Operating cash use increased from $1.861 million to $2.663 million.
- Net loss improved substantially from $35.385 million, largely because the prior-year quarter included a $33.937 million noncash expense from changes in warrant fair value. The current quarter’s warrant fair-value expense was $23,000; the year-over-year net-loss comparison is therefore not a direct indicator of operating improvement.
Outlook, risks and unusual items
- Management said cash on hand at June 30, together with expected collaboration receipts, was sufficient to fund planned operations for at least 12 months. After quarter-end, the company raised approximately $43.3 million net from an offering of 10.35 million shares, which materially increased available funding but also diluted existing shareholders.
- No specific revenue, earnings or cash-flow guidance was provided. Management said future funding needs were uncertain and additional financing might be required; insufficient funding could delay, reduce or end development programs.
- Warrant liabilities were valued using Level 3 assumptions, including stock-price volatility and financing probabilities; management cautioned that changes in inputs could cause significant quarter-to-quarter valuation swings.
- Organovo was in a dispute with Spencer Trask over alleged fees and confidentiality issues connected with warrant solicitations and prior financing arrangements. The company disputed the claims, had not accrued a loss because liability was not considered probable or estimable, and said an unfavorable outcome could materially affect business, liquidity or financial condition.
- After quarter-end, shares began trading on NYSE MKT in July 2013. The company also reported a $100 million shelf registration; this is an authorization, not proceeds raised. The August public offering closed August 7, 2013.
- Management reported disclosure controls and procedures were effective and no material change in internal control over financial reporting during the quarter. The filing reported no material change from previously disclosed risk factors.
Important facts for investors to verify
- Confirm the intended issuer: the provided metadata says Vivosim Labs, Inc., while the filing identifies Organovo Holdings, Inc.
- Review the August 2013 offering documents for net proceeds, share issuance and resulting dilution; distinguish the completed offering from the separate shelf-registration capacity.
- Assess cash burn against management’s runway statement, including the effect of increased research, hiring and operating costs.
- Track collaboration and grant revenue, product commercialization progress and whether operating expenses continue to grow faster than revenue.
- Monitor the Spencer Trask dispute and subsequent disclosures for developments, potential costs or changes in contingency assessment.
- Review outstanding warrants, options and equity plans for potential dilution, and the assumptions behind the warrant-liability valuation.